Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate ...
Clarivate Plc (NYSE: CLVT) is a global provider of “transformative intelligence,” combining high-value data with analytics and workflow solutions for customers such as academia, government, law firms, and life sciences organizations. The company’s services are designed to help users move from discovery to execution—supporting how research is planned, funded, conducted, ...Clarivate Plc (NYSE: CLVT) is a global provider of “transformative intelligence,” combining high-value data with analytics and workflow solutions for customers such as academia, government, law firms, and life sciences organizations. The company’s services are designed to help users move from discovery to execution—supporting how research is planned, funded, conducted, evaluated, and translated into real-world impact.
From a business perspective, Clarivate operates across several interconnected domains:
- Scholarly and research intelligence: Clarivate offers the Web of Science suite and related tools including InCites and Journal Citation Reports for research discovery, performance evaluation, and analytics. It also provides workflow and publishing support tools such as EndNote, ScholarOne, Converis, and related platforms.
- Life sciences decision support: In this area, products such as Cortellis and Newport Integrity are aimed at helping pharmaceutical and biotechnology organizations monitor competitive landscapes, assess market intelligence, and support development and launch planning.
- Intellectual property (IP) management: The Derwent product line—covering Derwent Innovation, Techstreet, and IP Professional Services—supports customers in evaluating originality, establishing freedom-to-operate boundaries, securing and analyzing patent protection, and understanding the competitive technological landscape.
- Trademark and digital brand protection: Clarivate includes solutions such as CompuMark (trademark screening/search/monitoring) and MarkMonitor (helping enterprises manage and strengthen their digital presence).
Product-wise, Clarivate’s approach typically involves enriching and organizing large-scale datasets and then packaging them into usable workflows—so customers can reduce manual effort, improve decision quality, and ensure better compliance across research, IP, and brand processes. The company’s offerings span the entire research and innovation lifecycle: from literature discovery and citation intelligence to IP analytics and operational support for commercialization.
Cost and delivery model considerations: Clarivate is largely software- and data-enabled, so revenue is generally supported by subscription-style access and enterprise licensing, with expert or service elements layered in where domain expertise is required (for example, in research evaluation and IP-related work). Because its “assets” are information systems, content/data enrichment pipelines, and analytics models, the cost structure often emphasizes platform development, content acquisition/enrichment, and ongoing customer support.
Financially, available market data for CLVT indicates a publicly traded profile with ongoing investment in operations; however, detailed unit economics (e.g., BOM-like breakdown) are not publicly provided in the supplied inputs. In general terms for the sector, major drivers include data processing and curation, cloud/IT infrastructure, and sales/CS costs for enterprise contracts.
Key people: Clarivate’s CEO is Matti Shem Tov (appointed as the company’s next CEO per the provided press-release information). Strategically, the company aligns product roadmaps around expanding data coverage, improving analytics/workflows, and strengthening domain-specific solutions for life sciences and IP.
Wishes/forward outlook (consistent with the company’s mission): customers typically want more complete and timely coverage, faster workflow enablement, better integration into existing research and legal operations, and improved transparency/traceability of the intelligence used for decisions. Clarivate’s stated mission—discovery, protection, and commercialization of research, innovations, and established brands—directly aligns with those priorities.
Operator: Hello, everyone. Thank you for joining us, and welcome to Clarivate's Q2 earnings conference call. After today's prepared remarks, we will host a question-and-answer session. To raise your hand, press star one. To withdraw your question, press star one again. I will now hand the conference over to Mark Donohue, Head of Investor Relations at Clarivate. Please go ahead.
Mark Donohue: Thank you, and good morning, everyone. Thank you for joining us for the Clarivate second quarter 2026 earnings conference call. As a reminder, this conference call is being recorded and webcast and is copyrighted property of Clarivate. Any rebroadcast of this information in whole or in part without prior written consent of Clarivate is prohibited. And the accompanying earnings call presentation is available on the Investor Relations section of the company's website. During our call, we may make certain forward-looking statements within the meaning of the applicable securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the business or developments in Clarivate's business to differ materially from the anticipated results, performance, achievements or developments expressed or implied by such forward-looking statements. Information about the factors that could cause actual results to differ materially from results and performance, can be found in Clarivate's filings with the SEC and on the company's website. Our discussion will include non-GAAP measures or adjusted numbers, Clarivate believes non-GAAP results are useful in order to enhance understanding of our ongoing operating performance but they are a supplement to and should not be considered in isolation from or as a substitute for GAAP financial measures. Reconciliation of these measures to GAAP measures are available in our earnings release and supplemental presentation on our website. With me today are Matti Shem Tov, Chief Executive Officer; Jonathan Collins, Chief Financial Officer and Michael Easton, Chief Accounting Officer. After our prepared remarks, we will open up the call to your questions. And with that, it is a pleasure to turn the call over to Matti.
Matti Shem Tov: Good morning, everyone, and thank you for joining us. The key messages today are straightforward. We are delivering on our commitment and now we have the building blocks in place to accelerate organic growth. During the quarter, we advanced our AI innovation roadmap, grew organic ACV year-over-year, maintained disciplined cost management, and strengthened our balance sheet through deleveraging. These actions will deliver further long-term value to shareholders. In the second quarter, we drove continued progress across the business. Organic ACV growth improved to 1.5% and profit margin has expanded to more than 42%. At the segment level, Academia & Government and Life Sciences & Healthcare, each delivered …